Compare GP & SXTP Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | GP | SXTP |
|---|---|---|
| Founded | 2010 | 2010 |
| Country | Canada | United States |
| Employees | N/A | N/A |
| Industry | Construction/Ag Equipment/Trucks | Biotechnology: Pharmaceutical Preparations |
| Sector | Consumer Discretionary | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 3.3M | 3.6M |
| IPO Year | 2013 | 2023 |
| Metric | GP | SXTP |
|---|---|---|
| Price | $0.68 | $0.90 |
| Analyst Decision | | Buy |
| Analyst Count | 0 | 2 |
| Target Price | N/A | ★ $3.70 |
| AVG Volume (30 Days) | ★ 1.4M | 291.4K |
| Earning Date | 11-17-2026 | 11-16-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ 36.77 |
| EPS | ★ N/A | N/A |
| Revenue | N/A | ★ $1,005,471.00 |
| Revenue This Year | $308.21 | N/A |
| Revenue Next Year | N/A | $70.00 |
| P/E Ratio | N/A | ★ N/A |
| Revenue Growth | N/A | ★ 65.49 |
| 52 Week Low | $0.19 | $0.34 |
| 52 Week High | $2.19 | $8.62 |
| Indicator | GP | SXTP |
|---|---|---|
| Relative Strength Index (RSI) | 39.51 | 49.87 |
| Support Level | $0.19 | $0.84 |
| Resistance Level | $1.19 | $1.00 |
| Average True Range (ATR) | 0.23 | 0.13 |
| MACD | -0.05 | 0.02 |
| Stochastic Oscillator | 20.08 | 85.25 |
GreenPower Motor Co Inc is a manufacturer and distributor of purpose-built, all-electric, zero-emission medium and heavy-duty vehicles serving the cargo and delivery market, shuttle and transit space and school bus sector. The Company operates in one reportable operating segment, being the manufacture and distribution of all electric commercial vehicles and transit, school and charter buses. Geographically the company has presence in Canada, and United States of America. The company generates majority of revenue from United States of America.
60 Degrees Pharmaceuticals Inc operates as a specialty pharmaceutical company with the goal of using biological science and applied research to develop and commercialize new therapies for the prevention and treatment of infectious diseases. Currently, company's pipeline under development covers development programs for vector-borne, fungal, and viral diseases utilizing three of the Company's future products: (i) new products that contain the Arakoda regimen of Tafenoquine; (ii) new products that contain Tafenoquine; and (iii) Celgosivir and/or botanical extracts from Australian Chestnut Trees.